“…Of the 33 studies that applied ML techniques to diagnose a hematological malignancy or to differentiate it from another disease state or malignancy ( Table 1 ), 18 were designed to establish and train ML models to discriminate gliomas [predominantly GBM from PCNSL ( 29 – 31 , 34 – 37 , 40 – 42 , 44 , 45 , 49 , 50 , 53 – 56 )] using features extracted from FDG-PET [one study ( 29 ),] or MRI ( 30 , 31 , 34 – 37 , 40 – 42 , 44 , 45 , 49 , 50 , 53 – 56 ) images. The remaining studies belonged to two major categories: those developing models to discriminate solid hematological malignancies from other benign and malignant lesions at other sites [nasopharyngeal carcinomas from nasopharyngeal lymphoma ( 46 , 48 ), idiopathic orbital inflammation from ocular adnexal lymphoma ( 33 ), thymic neoplasm from thymic lymphoma ( 14 ), breast carcinoma from breast lymphoma ( 15 ), lymphoma from normal nodes ( 43 ), or multiple myeloma from bone metastases ( 51 )] and those that detect the location of hematological malignancies either at diagnosis or during the disease course [location of ( 18 ) or evolving/residual lymphoma ( 32 ) or leukemia ( 17 ) or bone marrow involvement with multiple myeloma ( 16 , 38 , 47 , 52 ) or mantle cell lymphoma ( 39 )].…”